Gyre Therapeutics (GYRE) Non-Current Deffered Revenue (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Non-Current Deffered Revenue of $840000.0 for Q1 2026, down 7.18% year-over-year from $905000.0 in Q1 2025, and down 1.41% quarter-over-quarter from $852000.0 in Q4 2025.
Powered by 
Analysis
Gyre Therapeutics (GYRE) Non-Current Deffered Revenue (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Non-Current Deffered Revenue for 12 consecutive years, with $840000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Deffered Revenue fell 7.18% year-over-year to $840000.0; the TTM figure through Mar 2026 stood at $840000.0 (down 7.18% YoY), while the FY2025 annual figure was $852000.0, down 8.19% from the prior year.
- Non-Current Deffered Revenue retreated to $840000.0 in Q1 2026 per GYRE's latest filing, from $852000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $928000.0 in Q4 2024 and bottomed at $118000.0 in Q4 2022.
- Historically, Non-Current Deffered Revenue has averaged $562363.6 across 5 years, with a median of $840000.0 in 2026.
- On a YoY basis, Non-Current Deffered Revenue climbed as much as 368.11% in 2025 and fell as far as 8.19% in 2025.
- Gyre Therapeutics' Non-Current Deffered Revenue stood at $118000.0 in 2022, then soared by 80.51% to $213000.0 in 2023, then soared by 335.68% to $928000.0 in 2024, then declined by 8.19% to $852000.0 in 2025, then retreated by 1.41% to $840000.0 in 2026.
- Business Quant data shows GYRE's Non-Current Deffered Revenue at $840000.0 in Q1 2026, $852000.0 in Q4 2025, and $866000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 147.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Gyre Therapeutics | 691.38 Mn | 633.98 Mn | 26.90 Mn | 829,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 829,000.00 |
| Mar 31, 2026 | 840,000.00 |
| Dec 31, 2025 | 852,000.00 |
| Sep 30, 2025 | 866,000.00 |
| Jun 30, 2025 | 884,000.00 |
| Mar 31, 2025 | 905,000.00 |
| Dec 31, 2024 | 928,000.00 |
| Sep 30, 2024 | 185,000.00 |
| Jun 30, 2024 | 192,000.00 |
| Mar 31, 2024 | 203,000.00 |
| Dec 31, 2023 | 213,000.00 |
| Dec 31, 2022 | 118,000.00 |
| Dec 31, 2018 | 174,000.00 |
| Sep 30, 2018 | 161,000.00 |
| Jun 30, 2018 | 140,000.00 |
| Mar 31, 2018 | 135,000.00 |
| Dec 31, 2016 | 47,000.00 |
| Sep 30, 2016 | 18,000.00 |
| Jun 30, 2016 | 73,000.00 |
| Mar 31, 2016 | 183,000.00 |